# Junta clínica — PT-pseudo_fdd4ff09679e (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_fdd4ff09679e",
  "pid": "PT-pseudo_fdd4ff09679e",
  "task": 1,
  "psa": 4.4,
  "age": 62,
  "months": 1,
  "pirads": "5",
  "psad": 0.048,
  "psav": 0.75,
  "psap": 4.0,
  "vol": 91.11,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.78277797,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.4 ng/mL. PI-RADS 5. PSAD 0.05. Prostate volume 91 mL. csPCa 0.78.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "97 kg",
    "height": "180 cm",
    "bmi": "29.9",
    "bp": "133/72 mmHg",
    "hr": "70 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "12 Jan 2025",
  "enc_ref": "Dr. H. Martens (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment requested after previous prostate sampling and subsequent PSA elevation."
    },
    {
      "s": "History",
      "t": "At 62 years of age, this widowed gentleman entered evaluation in early 2023 due to an elevated PSA reading. Two subsequent biopsy procedures confirmed the prostate cancer diagnosis. He abstains from tobacco, consumes no alcohol, and manages moderate lower urinary tract symptoms, registering 13 points on the IPSS scale. Nocturia and acute urinary retention remain absent. A retired carpenter, he resides with his partner and dedicates weekends to hiking across nearby countryside. Cardiology evaluation in autumn 2024 indicated stable physiological parameters, while orthopaedic knee assessments reveal no functional restrictions. The patient historically favored adaptable clinic hours, though retirement has shifted that preference."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth; mobility: unremarkable; asymmetry: none. The examination confirms a normal DRE with a symmetrically enlarged prostate and firm capsule, lacking palpable nodules. Systemic assessment shows stable vital parameters. No lymphadenopathy or bone tenderness is evident."
    }
  ],
  "occupation": "retired carpenter",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Nephew",
  "recent_other": [
    "Orthopaedic outpatient — knee follow-up",
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 13/35 (moderate LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_fdd4ff09679e
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. H. Martens (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 62-year-old male
  - PSA: 4.4 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.048 ng/mL²
  - PSA velocity: 0.75 ng/mL/yr
  - Prior PSA: 4.0 ng/mL
  - Prostate volume: 91.11 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.78277797 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.4 ng/mL. PI-RADS 5. PSAD 0.05. Prostate volume 91 mL. csPCa 0.78.

Vitals: weight 97 kg, height 180 cm, BMI 29.9, BP 133/72 mmHg, HR 70 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested after previous prostate sampling and subsequent PSA elevation.

History: At 62 years of age, this widowed gentleman entered evaluation in early 2023 due to an elevated PSA reading. Two subsequent biopsy procedures confirmed the prostate cancer diagnosis. He abstains from tobacco, consumes no alcohol, and manages moderate lower urinary tract symptoms, registering 13 points on the IPSS scale. Nocturia and acute urinary retention remain absent. A retired carpenter, he resides with his partner and dedicates weekends to hiking across nearby countryside. Cardiology evaluation in autumn 2024 indicated stable physiological parameters, while orthopaedic knee assessments reveal no functional restrictions. The patient historically favored adaptable clinic hours, though retirement has shifted that preference.

Physical examination: DRE — texture: smooth; mobility: unremarkable; asymmetry: none. The examination confirms a normal DRE with a symmetrically enlarged prostate and firm capsule, lacking palpable nodules. Systemic assessment shows stable vital parameters. No lymphadenopathy or bone tenderness is evident.

Patient info: retired carpenter; Widowed; Lives with partner.
Next of kin: Nephew.

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Hiking on weekends; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Orthopaedic outpatient — knee follow-up; Cardiology — annual review (stable, autumn 2024).
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.62
  uncertainty  +/- 0.11 epistemic (95% band 0.41-0.83); among patients I cannot tell apart the outcome was 0.96 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.75: PI-RADS 5, PSA 5.5, PSAD 0.12, age 71, DRE Normal -> BIOPSY (clear). He wrote: "Prev biopsy finding is left lobe, MRI finding highly suspicious of ISUP≥2 on right side. Active surveillance, only 1 biopsy session performed (of unclear date and unclea…"
  2. distance 1.76: PI-RADS 5, PSA 4.2, PSAD 0.06, age 67, DRE Nodus -> DEFER (uncertain). He wrote: "Need to know if the lesion has grown or if it is stabile."
  3. distance 1.78: PI-RADS 5, PSA 11.0, PSAD 0.108, age 70, DRE Normal -> BIOPSY (borderline). He wrote: "Patient on Activ Surveillance with severe LUTS symptoms. There are two options , recommend surgery direkt or do a new biopsy."

PRECEDENT: BIOPSY (weighted vote 0.67 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy is mandated when there is a suspicion of histological progression on MRI. "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy." This requires establishing if the current MRI findings suggest progression that warrants a biopsy.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline requires an MRI finding to mandate a repeat biopsy, which is not established here. The cohort criterion correctly notes that the prior positive biopsy means the decision hinges on the documented grade of that prior biopsy and surveillance history, which is what the panel does not resolve.

WHAT WE STILL NEED
The panel already contains the following known facts:
*   Prior biopsy status: Positive. This is crucial as the guideline suggests histopathology criteria are the strongest reason to trigger a change in management.
*   PI-RADS score: 5. This is important as the guideline mentions that targeted and perilesional biopsies should be taken for lesions with PI-RADS $\ge 3$.
*   PSA: 4.4 ng/mL. This is important as the guideline mentions that a PSA change alone should not change management based on its weak link with grade progression.
*   Prior biopsy grade: Positive. This is important as the guideline states that histopathology criteria are the strongest reason to trigger a change in management.
*   Months since last PSA: 1. This is important as the guideline suggests a repeat PSA test after four weeks if the PSA is in the 3-10 ng/mL range.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the documented grade and surveillance status from the previous notes, as the guideline requires an MRI finding to mandate a repeat biopsy.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the mpMRI prose suggest histological progression that mandates a repeat biopsy?
  psa_trend (get_psa_trend) -> Does the PSA trend suggest a change in management based on the EAU guideline criteria?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy, the number and dates of biopsy sessions, and surveillance status?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Prostate MRI | Facility: Amsterdam UMC (AMC) | Date: 10 Jan 2025
Does the mpMRI prose suggest histological progression that mandates a repeat biopsy?
The mpMRI prose describes a "focal hypointense area within the left peripheral zone at the base and mid sections, spanning roughly 28 mm" with "marked restriction paired with depressed ADC values" and "early, localized enhancement." This finding is presented as a PI-RADS 5 lesion, but the report does not explicitly state that this finding *mandates* a repeat biopsy according to the EAU guideline.

psa_trend
Does the PSA trend suggest a change in management based on the EAU guideline criteria?
The PSA trend shows a value of "4.4 ng/mL" on "Jan 2025," which is an increase from "1.1 ng/mL" in "Mar 2024," which is an increase from "1.5 ng/mL" in "May 2023." This trend is noted, but the EAU guideline states a PSA change alone should not change management based on its weak link with grade progression.

previous_notes
What is the documented grade of the prior biopsy, the number and dates of biopsy sessions, and surveillance status?
The documented grade of the prior biopsy is "ISUP GG 2" from "14 Sep 2024." There have been "Two subsequent biopsy procedures" mentioned in the initial record, and the notes indicate a review of the updated histology occurred. Surveillance status is not explicitly stated as "confirmatory biopsy due" in the retrieved notes.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes provided sufficient information regarding the prior biopsy and surveillance status.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS score of 5 on the mpMRI.
The PSA trend shows a recent increase to 4.4 ng/mL.

Findings that argue AGAINST sampling this patient now:
The EAU guideline requires an MRI finding to mandate a repeat biopsy, which is not explicitly established in the report prose.
The documented prior biopsy grade is ISUP GG 2.

WHERE THIS LEANS
The documents confirm a high-risk MRI finding and a rising PSA, but the EAU guideline suggests the MRI finding alone is insufficient to mandate a repeat biopsy without evidence of histological progression.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.40 ng/mL over 3 points spanning 20 months; velocity +1.74 ng/mL per year; doubling time about 13 months.
PROJECTION at 6 months: 6.6 ng/mL, conformal 95% band 1.9-23.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.60
  uncertainty  +/- 0.10 epistemic (95% band 0.40-0.80), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.62  ('supports' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.60  ('discuss' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.67  (k=3 precedents)

  documented prior grade in the opened documents: GG 2 ("ISUP GG 2")

RULE THAT FIRED: documented prior grade GG 2 (ISUP GG 2) — carried by documented grade.
PANEL ANSWER: NO BIOPSY. A documented grade group of 2 or more is a treatment problem, not a sampling problem: the reading urologist deferred re-biopsy in 7 of the 8 labelled men with a recorded GG >= 2.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-FUSION, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—directly address the moderator's questions. The registrar retrieved the documented prior biopsy grade and surveillance status from the previous_notes, and the MRI prose was retrieved.

ALIGNMENT WITH THE PANEL
The retrieved finding, the documented prior biopsy grade of "ISUP GG 2," aligns with the PANEL-PROTOCOL's answer of "NO BIOPSY," as the protocol states that a documented grade group of 2 or more is a treatment problem, not a sampling problem.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy? Answered by the registrar: "ISUP GG 2" from "14 Sep 2024."
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Answered by the registrar: "Surveillance status is not explicitly stated as 'confirmatory biopsy due' in the retrieved notes."

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade (ISUP GG 2) carries the most weight because the PANEL-PROTOCOL explicitly states this finding is the rule that fired, indicating it overrides the other expert bids.

MY SUGGESTION TO THE CHAIR
I suggest the panel's decision of NO BIOPSY should stand firmly, as the retrieved evidence directly supports the protocol's conclusion based on the documented prior pathology grade.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision to defer biopsy is based on the documented prior biopsy grade of ISUP GG 2, which the panel protocol identifies as a treatment problem rather than a sampling problem. This finding overrides expert suggestions, as the guideline requires evidence of histological progression to mandate a repeat biopsy. The evidence converged on deferral because the documented prior pathology grade was the decisive factor.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
